anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Conventional chemotherapy and also high dose chemotherapy with autologous stem cell transplantation are not curative treatment options in B-CLL; nearly all patients will eventually relapse. Also monoclonal antibodies are not curative for B-CLL patients in monotherapy, their impact on survival in combination with conventional chemotherapy is currently validated. In addition, there is no standard combination therapy for patients with relapsed CLL. Therefore there is an urgent medical need to identify new strategies.

The combination of rituximab (monoclonal antibody) and bendamustine (chemotherapy) has shown encouraging activity in patients with relapsed/refractory NHL or mantle cell lymphoma. In vitro studies have been used to investigate the effects of bendamustine and rituximab on programmed cell death (apoptosis) and have shown synergistic effects of both drugs. The mechanisms of action of these two active drugs may provide a treatment with good therapeutic potential in CLL. However, though bendamustine has been used for over 30 years there is still a need to define a standard regimen for the use of bendamustine in combination with monoclonal antibodies (mAb) especially in the treatment of CLL.
Carefully consider the potential benefits and risks of tolmetin and other treatment options before deciding to use tolmetin sodium. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).

After observing the response to initial therapy with tolmetin sodium, the dose and frequency should be adjusted to suit an individual patient's needs.

For the relief of rheumatoid arthritis or osteoarthritis, the recommended starting dose for adults is 400 mg three times daily (1200 mg daily), preferably including a dose on arising and a dose at bedtime. To achieve optimal therapeutic effect the dose should be adjusted according to the patient's response after 1 or 2 weeks. Control is usually achieved at doses of 600 mg to 1800 mg daily in divided doses (generally t.i.d.). Doses larger than 1800 mg/day have not been studied and are not recommended.

For the relief of juvenile rheumatoid arthritis, the recommended starting dose for pediatric patients (2 years and older) is 20 mg/kg/day in divided doses (t.i.d. or q.i.d.). When control has been achieved, the usual dose ranges from 15 to 30 mg/kg/day. Doses higher than 30 mg/kg/day have not been studied, and, therefore, are not recommended.

A therapeutic response to tolmetin sodium can be expected in a few days to a week. Progressive improvement can be anticipated during succeeding weeks of therapy. If gastrointestinal symptoms occur, tolmetin can be administered with antacids other than sodium bicarbonate. Tolmetin sodium bioavailability and pharmacokinetics are not significantly affected by acute or chronic administration of magnesium and aluminum hydroxides; however, bioavailability is affected by food or milk (see PRECAUTIONS: Drug-Food Interaction).
The invention relates to a method for the identification and/or production of an inhibitor of hair production. Moreover, the invention relates to a method for the inhibition of hair production. The invention also relates to a method for the production of a pharmaceutical composition. Furthermore, the invention relates to a pharmaceutical composition comprising an inhibitor of hair production identified or obtained according to one of the methods of the invention or a polynucleotide coding for the inhibitor, optionally in a pharmaceutically acceptable form of administration. The invention also relates to a pharmaceutical composition which comprises a polypeptide comprising the DNA-binding domain but not the transactivator domain of Whn, LEF-1 or Hoxc13, or a polynucleotide coding for said polypeptide, optionally in a pharmaceutically acceptable form of administration. Moreover, the invention relates to the use of a polypeptide comprising the DNA-binding domain but not the transactivator domain of Whn, LEF-1 or Hoxc13, or a polynucleotide coding for said polypeptide, of an inhibitor identified or obtained according to one of the methods of the invention or of a polynucleotide coding for such an inhibitor for the production of a pharmaceutical composition for the treatment of hair growth disorders. Not least, the invention relates to a kit for carrying out the methods of the invention.
With high antiviral potency and low drug resistance rate, both ETV and tenofovir disoproxil fumarate (TDF) have been recommended as the first-line antiviral therapy for chronic hepatitis B (CHB). However, risk of renal dysfunction remains an issue in TDF long-term therapy. Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir and is formulated to deliver the active metabolite to target cells more efficiently than TDF at lower doses, thereby reducing systemic exposure to tenofovir. Importantly, TAF had improved renal safety as compared to TDF. TAF has been approved for treating CHB since 2017; however, it is still unknown whether the efficacy and renal safety of TAF is compatible to those of ETV. The investigators aim to conduct an open label, randomized controlled trial comparing TAF with ETV for assessing their efficacy and renal safety in CHB patients. The eligible CHB patients are randomly assigned (1:1) to receive TAF or ETV. After allocation to TAF group or ETV group, study subjects will receive therapy for 3 years (144 weeks).
Arsenic is a well-known environmental toxicant and emerging evidence suggests that arsenic exposure has potential skeletal muscle toxicity; however, the underlying mechanism has not yet been clarified. The aim of this study was to investigate the correlation among adverse effects of subchronic and chronic environmental arsenic exposure on skeletal muscle as well as specific myokines secretion and angiotensin II (AngII)-melatonin (MT) axis in rats. Four-week-old rats were exposed to arsenite (iAs) in drinking water at environmental relevant concentration of 10 ppm for 3 or 9 months. Results indicated that the gastrocnemius muscle had atrophied and its mass was decreased in rats exposed to arsenite for 9 months, whereas, they had no significant changes in rats exposed to arsenite for 3 months. The levels of serum-specific myokine irisin and gastrocnemius muscle insulin-like growth factor-1 (IGF-1) were increased in 3-month exposure group and decreased in 9-month exposure group, while serum myostatin (MSTN) was increased significantly in 9-month exposure group. In addition, serum AngII level increased both in 3- and 9-month exposure groups, while serum MT level increased in 3-month exposure group and decreased in 9-month exposure group. Importantly, the ratio of AngII to MT level in serum increased gradually with the prolongation of arsenite exposure. It showed a certain correlation between AngII-MT axis and gastrocnemius muscle mass, gastrocnemius muscle level of IGF-1 or serum levels of irisin and MSTN. In conclusion, the disruption of AngII-MT axis balance may be a significant factor for skeletal muscle atrophy induced by chronic environmental arsenic exposure.
This invention relates to materials and methods for detecting and modulating the activity of RNA. The invention generally relates to the field of "antisense"  compounds, compounds which are capable of specific hybridization with a nucleotide sequence of an RNA. In accordance with preferred embodiments, this invention is directed to the design, synthesis and application of oligonucleotides and to methods for achieving therapeutic treatment of disease, regulating gene expression in experimental systems, assaying for RNA and for RNA  products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins and cleaving RNA in site specific fashions.   It is well known that most of the bodily states in mammals including most disease states, are effected by proteins. Such proteins, either acting directly or through their enzymatic functions, contribute in major proportion to many diseases in animals and man.  Classical therapeutics has generally focused upon interactions with such proteins in efforts to moderate
At least 12 hours before surgery: Infusion of levosimendan (0,1 mcg/kg/min). 24 hours of infusion without a bolus.
BACKGROUND: Back pain is a huge global problem. For some people, the pain is so severe that they feel the need to present to an emergency department (ED). Our aim was to explore patient and staff perspectives for the development of a digital care pathway (DCP) for people with back pain who have presented to ED, including acceptability, barriers and facilitators.
METHODS: We used a descriptive phenomenology approach using semi-structured interviews with patient and staff participants at a tertiary hospital. Interviews were transcribed and data codes were developed using inductive thematic analysis. Themes were discussed between researchers until consensus was achieved.
RESULTS: A total of 16 interviews were carried out, half of which involved patient participants. We identified three major themes: (i) expectations and experiences of staff and patients with low back pain in ED; (ii) a digital care pathway can empower patients and support clinicians in providing care; and (iii) acceptability, barriers, facilitators and recommendations of engaging with a DCP to track the trajectory of back pain. Each theme was further categorised into subthemes.
CONCLUSION: Introducing a DCP was perceived as acceptable and beneficial by patients and staff. Both groups were aware of the potential participant burden if surveys were too long. Introducing a DCP could be a valuable adjunct to current management care models, providing a standardised source of education with the potential for individualised tracking and monitoring. The design and development of a DCP will need to consider reported facilitators and address perceived barriers for engagement.
PATIENT OR PUBLIC CONTRIBUTION: This project sought insights from patients and staff about a digital care pathway. This forms the first step of patient and consumer consultation before implementing a digital care pathway. All consumers were offered the opportunity to review their responses and our interpretation.
FIELD: medicine. ^ SUBSTANCE: invention concerns feeding of cats and dogs. A weight-reduction composition contains tyrosine in amount not exceeding approximately 0.4 wt %, particularly in amount approximately 0.08 to approximately 0.38 wt % and preferentially approximately 0.2 to approximately 0.36 wt % on solids. Method of animal's weight reduction implies that it is considered whether an animal requires weight reduction and feeding an animal with overweight with feed containing a composition with low content of tyrosine. Method of decreasing food consumption provides feeding of an animal with overweight with feed containing said composition. The feed additive, additional food or delicacy for weight reduction in dogs and the cats contain tyrosine in amount less than 0.4 wt % on solids. ^ EFFECT: invention allows reducing weight in domestic animals with overweight or obesity. ^ 24 cl, 4 dwg, 5 tbl
The dose of cefazolin and Ceftazidime co-administered were 20 mg /kg，they were given intraperitoneal twice daily in the first bag and the fourth bag for 5 days，and given 1g once daily in the fourth bag for 9 days. Total treatment duration was 2 weeks.
In this study, expectant mothers who used epidural anesthesia to reduce pain during delivery in the delivery room of a central medical center, including primiparous women and menstrual women, were evaluated for compliance with the acceptance criteria through the mother's manual and maternity examination data. The maternal agreed to fill out the subject consent form,After obtaining the consent form of the test subject, it is included in the research object of this trial. It is expected that 190 expectant mothers will be accepted, and 40 expectant mothers will be accepted. The research tool uses the Chinese version of the Mackey Childbirth Satisfaction Rating Scale to measure women's satisfaction with the behavioral performance of self, partner, and baby during delivery / production. The scale was agreed by the original author and translator. Use consists of six levels: overall satisfaction (3 questions), self-satisfaction (9 questions), newborns (3 questions), midwifery care workers (9 questions), physicians (6 questions), and Satisfaction with partners (2 questions), a total of 32 items. After data collection, the data will be archived and analyzed with Statistical Package for the Social Sciences (version 22.0) software.
The invention discloses a medicament for treating chronic rhinitis. The medicament is prepared from poria cocos, radix angelica sinensis, atractylodes macrocephala koidz, radix angelicae, radix paeoniae rubra, Liriodendron chinensis (Hemsl.) Sarg., leaves of tree of heaven, calamine, fructus xanthii, pericarpium citri reticulatae, fructus aurantii immaturus, radix puerariae, asarum and fruits of Kwangsi Dutchmanspipe. The medicament is in the form of capsules. The preparation process of the medicament includes the steps of grinding, gelatin liquid forming achieved through mixing, soft gelatin sheet preparing, finished product pressing and the like. Compared with the prior art, the medicament has functions of tonifying lungs and spleens, warming channels and expelling cold, eliminating stagnation and dispersing blood stasis, nourishing qi and tonifying blood, relieving superficies syndrome with pungent and warm natured drugs, regulating ying and wei, promoting body fluid secretion and moistening dryness, clearing heat and dispersing evil, promoting qi to activate blood and eliminating focus, removes underlying causes, and is high in target performance, high in practicability and ideal in treatment effect.
BACKGROUND: High-level evidence supporting the role of repeat transurethral resection (reTUR) in non-muscle-invasive bladder cancer (NMIBC) is lacking. A randomized controlled trial (RCT) assessing whether immediate reTUR has an impact on patient prognosis is essential. However, since such a RCT will require enrollment of a high number of patients, a preliminary feasibility study is appropriate.
OBJECTIVE: To assess the feasibility of an RCT investigating the impact of immediate reTUR + adjuvant bacillus Calmette-Guérin (BCG) versus upfront induction BCG after initial TUR in NMIBC.
DESIGN, SETTING, AND PARTICIPANTS: Eligible patients were randomly assigned to receive either reTUR + adjuvant BCG or upfront induction BCG after TUR. Patients with macroscopically completely resected high-grade T1 NMIBC, with or without concomitant carcinoma in situ, and with detrusor muscle (DM) present in the initial TUR specimen were considered eligible for inclusion. Exclusion criteria included lymphovascular invasion (LVI), histological subtypes, hydronephrosis, concomitant upper tract urothelial carcinoma (UTUC), or urothelial carcinoma within the prostatic urethra. The aim was to enroll 30 patients in this feasibility study.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The patient recruitment rate was the primary outcome. Oncological outcomes (recurrence-free and progression-free survival) were secondary endpoints.
RESULTS AND LIMITATIONS: Overall, 30 patients (15 per arm) were randomized over a period of 14 mo (August 2020-October 2021). Two eligible patients refused the randomization, resulting in a patient compliance rate of 93.3% for the study protocol. We excluded 49 ineligible patients before randomization because of histological subtypes (n = 16, 33%), LVI (n = 9, 18%), DM absence in the TUR specimen (n = 12, 24%), metastatic disease (n = 5, 10%), concomitant UTUC (n = 3, 6%), or hydronephrosis (n = 4, 8%). At reTUR, persistent disease was found in four patients (29%) and upstaging to muscle-invasive disease in one (7%). Over median follow-up of 17 mo, disease recurrence was detected in three patients (23%) in the reTUR arm and six patients (40%) in the upfront BCG arm. Progression to muscle-invasive disease was observed in one patient treated with upfront BCG.
CONCLUSIONS: The feasibility of conducting an RCT comparing upfront BCG versus reTUR + BCG in high-grade T1 NMIBC has been demonstrated. Our results underline the need to screen a large number of patients owing to characteristics meeting the exclusion criteria in a high percentage of cases.
PATIENT SUMMARY: We found that a clinical trial of the role of a repeat surgical procedure to remove bladder tumors through the urethra would be feasible among patients with high-grade non-muscle-invasive bladder cancer. These preliminary results may help in refining the role of this repeat procedure for patients in this category.
In the pre-study, venous samples were collected in paired 2 mL ABG syringes and 4.5 mL tubes from each of the 10 patients, to determine which blood collection method was preferred. VBG samples were collected via a butterfly needle with a three-way stopcock in conjunction with routine venous blood sampling upon admission. VBG samples were collected by the biomedical laboratory technician in the same manner as PVB samples in the normal clinical setting. Results from the pre-study were used to determine the preferred blood collection method in the main study. In this study, paired ABG and VBG samples were collected simultaneously from each of the 20 patients. The ABG samples were collected by the responsible physician. Allocation to either the pre-study or the main study was performed by simple quasi-random allocation in order of admission.
ESWT (EMS Swiss DolorClast® Classic) application will be applied to patients in groups 1 and 3 with a frequency of 15 Hz, a 2000 shock wave and an energy density of 2.5 bar. In practice, patients will be asked to lie in the prone position and keep the knee and hip joints in a neutral position. By placing a towel roll under the ankle, the heel will be stabilized to be applied. Using the ultrasound gel as an intermediate, the ESWT device will be applied to the medial part of the calcaneus.
<P>PROBLEM TO BE SOLVED: To provide a preparation in which a sparingly soluble component containing a ceramide, sterols represented by vegetable sterols or their glycosides and bringing out preferable action on the skin and the hair is stably formulated.  <P>SOLUTION: The composition for external use comprises (1) a ceramide, (2) a sterol or its glycoside, (3) a cationic surfactant represented by general formula (1) äwherein R1 and R2 are each independently a 1-4C alkyl group; R3 and R4 are each independently a 10-24C alkyl group or alkenyl group; X-a is a mineral acid radical and (a) is an integer of 1-3} and (4) a phospholipid. A ceramide type 2 is preferably used as the ceramide and the ceramide content is preferably 0.01-5 mass%. A material selected from campesterol, sitosterol, stigmastanol and stigmasterol is preferably used as the sterol or the sterol part of glycoside of the sterol to constitute the glycoside of the sterol. A glucose is preferably used as a sugar part.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Gene carriers with the use of β-1,3-glucans. A β-1,3-glucan has at least one 1,6-glucopyranoside branch in its repeating unit. It is chemically modified by oxidation with periodic acid and reductive amination, etc. to thereby acquire a functional group bonding to nucleic acid (for example, a cationic functional group) at least in a part of its branch. By dissolving in a polar organic solvent, β-1,3-glucan triple helix is disassembled into single strands. By replacing the polar organic solvent containing the chemically modified single-stranded β-1,3-glucan by water, a complex (gene carrier) composed of the acid bonded to the double-stranded β-1,3-glucan is formed.
The utility model relates to an analgesic plaster for treating heart diseases, which comprises the lining layer of an outer surface, a nitroglycerin medicine layer, a controlled release layer, an allergy reducing adhesion layer, and a plastic paper protective layer, wherein, the utility model is provided with a plurality of ventilation holes; the ventilation holes are arranged from the lining layer of an outer surface to the allergy reducing adhesion layer; the center of the allergy reducing adhesion layer adheres to a massage block. In use, the plastic paper protective layer is torn off. The utility model is stuck at a front breast. The massage block thereof is aimed at a Shanzhong acupoint. The massage block of the back is aimed at any one of two Xinshu acupoints. The analgesic plaster not only has the advantages of elasticity and ventilation, but also has the advantages that the analgesic plaster can carry out massage, can be applied for a long term, can strengthen curative effects, and has a health-care function.
Participants in the intervention group will be offered four one-day group workshops (2-3 hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) Sports. The workshops will be offered online via Zoom and will be video recorded. The intervention group will also receive information (activity booklets via the Fit Families App) and physical education (physical activity)-related equipment, which will be mailed to them. At the end of the workshop parents will be instructed to practice the skills they learned with their child for the next 3 weeks (for at least 3 hrs per week).
Diabetic kidney disease (DKD) is the predominant type of end-stage renal disease. Increasing evidence suggests thatglomerular mesangial cell (MC) inflammation is pivotal for cell proliferation and DKD progression. However, the exactmechanism of MC inflammation remains largely unknown. This study aims to elucidate the role of inflammatoryfactor high-mobility group box 1 (Hmgb1) in DKD. Inflammatory factors related to DKD progression are screened viaRNA sequencing (RNA-seq). In vivo and in vitro experiments, including db/db diabetic mice model, CCK-8 assay, EdUassay, flow cytometric analysis, Co-IP, FISH, qRT-PCR, western blot, single cell nuclear RNA sequencing (snRNA-seq),are performed to investigate the effects of Hmgb1 on the inflammatory behavior of MCs in DKD. Here, wedemonstrate that Hmgb1 is significantly upregulated in renal tissues of DKD mice and mesangial cells cultured withhigh glucose, and Hmgb1 cytopasmic accumulation promotes MC inflammation and proliferation. Mechanistically,Hmgb1 cytopasmic accumulation is two-way regulated by MC-specific cyto-lncRNA E130307A14Rik interaction andlactate-mediated acetylated and lactylated Hmgb1 nucleocytoplasmic translocation, and accelerates NFκB signalingpathway activation via directly binding to IκBα. Together, this work reveals the promoting role of Hmgb1 on MCinflammation and proliferation in DKD and helps expound the regulation of Hmgb1 cytopasmic accumulation in twoways. In particular, Hmgb1 may be a promising therapeutic target for DKD.
The study was designed to be randomly controlled. Block randomization method was used to determine the intervention and control groups. Randomization was done by a biostatistician outside the researcher. 50 nursing students were randomly assigned to the intervention and control groups. The study was carried out in three stages with three EFT applications, applied for approximately 20-30 minutes, at 7-day intervals. In the first stage, students who met the inclusion criteria were identified by interviewing students who thought they had a fear of childbirth. After informed consent was obtained from the students and pretest data were collected, they were randomly assigned to intervention and control groups. EFT application was applied to those in the intervention group. No intervention was made for the control group. Data was collected twice for the intervention group, before the first EFT application (pretest) and after the last EFT application (posttest). The control group was also tested at the first interview and again 3 weeks later. The applications were carried out face to face with the students as a group. For the collection of research data, "Descriptive Information Form", "General Self-Efficacy (GSE) Scale", "Perceived Stress Scale" and "The Subjective Units of Distress (SUD) Scale" were used.